Viribus Expands Its E-Trike Lineup with FC1 and FC2 Folding Electric Tricycles

ONTARIO, Calif., Oct. 8, 2025 /PRNewswire/ -- Viribus has unveiled its newest line of folding electric tricycles for adults: the FC1 Folding Electric Tricycle and the FC2 Folding Electric Tricycle. 

Representing a fresh look and feel for folding adult tricycles, these high-performing tricycles bring new and interesting features and updates that redefine the limits of what a folding three-wheeled electric tricycle can deliver to everyday riders and enthusiasts.

With the release of the FC1 and FC2, Viribus continues to meet the precise needs of both performance-oriented riders seeking thrill and adventure, and city-based utility-oriented commuters seeking the perfect vehicle for everyday life mobility needs.

The Viribus FC1 Folding Electric Tricycle: Built for Power and Stability

The Viribus FC1 is designed for riders who want the stability and safety of a three-wheel bike, but also the power and muscle of a serious vehicle.  It is equipped with a 750-watt motor capable of surging to 1,200 watts at peak performance, delivering 80 N•m of torque for steep climbs (up to 15 degrees) and heavy loads.

The 48V 15Ah Samsung battery is UL-2271 certified and capable of covering up to 62 miles on pedal assist or 36 miles on throttle alone, all at a quick charging speed of just five hours.

Its fat 20″ × 2.6″ Kenda tires are puncture-resistant, designed for traction on both pavement and off-road terrain.

Standout Features

The FC1 presents to triker three new, unique features specific to this model:

• A triple hydraulic disc braking system, with one disc on the front and one on each rear wheel, for more precise braking and tighter control on challenging terrain.
• A rear differential lock to balance torque between both rear wheels, and guarantee a seamless riding experience.
• Seatpost suspension: In addition to the traditional front and rear suspension systems, the FC1 has a seatpost suspension for better shock absorption and more comfortable riding on rough terrain and/or over longer distances.

With a 7-speed gear system, a 3.5″ color display with USB charging, and NFC keyless access with four included cards, the FC1 delivers the perfect balance of performance, safety, and accessibility features for daring trikers who demand more from their tricycles.

Early User Experience

The opinions of early users have centered around the higher performance and speed of the FC1 as well as its better gearing and stability over challenging terrain.

"I was honestly blown away by how sturdy and responsive it felt," says Alex, a long-time customer who participated in a product testing event. " It handled the hills without breaking a sweat, and the ride was so smooth…I mainly see myself using it for long commutes and for taking on activities  I would not normally think to do with a trike…..  This is a big step up from any trike I've ridden before."

The Viribus FC2 Folding Electric Tricycle: Folding Flexibility for Urban Life

Complementing the FC1, the Viribus FC2 Folding Electric Tricycle offers a balanced blend of performance and practical features to meet the most practical everyday riding needs of trikers. 

With the same 750W motor and 80 N•m torque performance backbone, the FC2 features urban-focused innovations like a 2-step folding system that reduces its size to just 42.3" × 24.6" × 30.6" for easy storage in apartments, offices, or even car trunks. This is the perfect tricycle for riders who relish the daily routine of city life.

What sets the FC2 apart for city use is its thoughtfully engineered flexibility. It is designed to be compact and comes with exclusive features to save riders time, energy, and costs on a daily basis.

The 2-step folding system and compact folded size make it manageable in small apartments, office elevators, shared storage areas, or car trunks. It arrives 95% pre-installed, and assembly typically completes in under 30 minutes.

Special Features

• Hydraulic 180 mm disc brakes ensure dependable stopping power in varied weather conditions.
• A differential mechanism balances power to both rear wheels for smoother turning and greater stability.
• A dual rear suspension system to enhance ride comfort over potholes, curbs, or uneven surfaces.
• NFC keyless access (four cards included) allows secure, quick starts for multiple riders.
• The FC2 is equipped with IPX4 water resistance, a parking brake, and a  USB-C charging port for mobile devices.

With a payload capacity of 400 lb and reinforced baskets (front 11 lb, rear 110 lb), the FC2 is suited for errands, groceries, or personal cargo. Its top speed of 20 mph keeps it within typical urban e-bike regulations. 

Early User Experience

"Just from the design, you can tell it's a trike designed for busy riders on the go," says Anne-Lynn, another participant in early testing,  " and you certainly get that feeling when you hop on. It is really compact, and you can see how the new smart features help handle hassle parking, storing, and maintenance….Perfect for busy riders who need to get stuff done quickly."

Two Solutions, One Mission

By offering both the FC1 and FC2, Viribus is giving riders a choice between power and stability or flexibility and portability for all riders. Both trikes share the brand's commitment to safety, convenience, and modern mobility with hydraulic braking systems, certified batteries, and thoughtful designs tailored to real-world use.

By releasing both the FC1 and FC2 together, Viribus underscores its vision of making electric tricycles practical for all riders, whether you're looking for power and performance or safety and everyday usability.

• FC1 = Performance + Adventure (younger, active adults)
• FC2 = Stability + Convenience (older adults seeking everyday practicality)

A Word From Viribus

"The FC1 and FC2 reflect two sides of the same goal: to make e-mobility more accessible, practical, and enjoyable. Whether you need raw power and carrying strength, or a folding solution for tight urban spaces, Viribus has built a trike that fits."

Viribus FC1 and FC2: Both Available Now!

The Viribus FC1 and Viribus FC2 Folding Electric Tricycle are both available now at viribusbikes.com, starting at US $1,999. 

Each model comes with free shipping, a 30-day return policy, and a one-year warranty, along with optional professional assembly through Viribus' Vi-Build service.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Viribus Expands Its E-Trike Lineup with FC1 and FC2 Folding Electric Tricycles

HIGHLIGHTS

• Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol.

Patient population

• With the SECuRE trial continuing to recruit, a total of nine participants who had evaluable data by the 25^th of November 2025 were included in the interim assessment by the SRC, with the majority of participants receiving at least two cycles of 8 GBq of ⁶⁷Cu-SAR-bisPSMA each by the data cut-off date.
• Seven participants received ⁶⁷Cu-SAR-bisPSMA and two participants were treated with a combination of ⁶⁷Cu-SAR-bisPSMA with enzalutamide.
• Most participants were heavily pre-treated (with 55.6% having received more than 5 previous anti-cancer regimens) and had bone metastasis (66.7%).

Safety

• The safety profile of ⁶⁷Cu-SAR-bisPSMA remains favourable with most related adverse events (AEs) in the Cohort Expansion to date being Grade 1 or 2. The most common AEs were nausea and lymphopenia (observed in 33.3% of participants, for each AE).

Efficacy

• Six participants had at least two prostate specific antigen (PSA) results following ⁶⁷Cu-SAR-bisPSMA administration, with all showing a decrease in PSA. Of those, four participants (66.7%) thus far had a reduction of more than 50% in PSA (PSA50) and two participants (33.3%) had a reduction of more than 80% (PSA80).
• One participant who presented with bone metastasis at enrolment achieved undetectable PSA with no prostate cancer detected by computed tomography (CT) or bone scan following ⁶⁷Cu-SAR-bisPSMA treatment. The participant reported having excellent quality of life following the treatment.

Next Steps

• The SECuRE trial will continue enrolment into the Cohort Expansion Phase with planned completion of recruitment in 2026. Phase III registrational trial planning ongoing based on data generated to date.

SYDNEY, Jan. 15, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to share a number of updates on the SECuRE trial following an SRC meeting. The SRC has recommended that the trial continue with the Cohort Expansion Phase (Phase II) as planned with no modifications to the protocol. The interim results assessed by the SRC were collected from nine participants enrolled in the cohort that had evaluable data by the cut-off date of the 25^th of November 2025 and continue to show promising efficacy and a favourable safety profile of ⁶⁷Cu-SAR-bisPSMA.

The majority of the nine participants had bone metastasis at enrolment (66.7%) and received multiple lines of previous treatments (more than 5 previous anti-cancer regimens, 55.6%). Median PSA prior to ⁶⁷Cu-SAR-bisPSMA treatment was 18.9 ng/mL (range 1.5-30.2 ng/mL). Six out of these nine participants received at least 2 cycles of 8 GBq of ⁶⁷Cu-SAR-bisPSMA each, with two of them also receiving concomitant enzalutamide.

Of the nine participants included in this SRC analysis, six had at least two PSA results following their ⁶⁷Cu-SAR-bisPSMA treatment by the data cut-off date. Of these six participants, thus far four (66.7%) showed reductions in PSA of 50% or more (PSA50) and two (33.3%) showed reductions of 80% or more (PSA80).

The safety profile of ⁶⁷Cu-SAR-bisPSMA remains favourable in the Cohort Expansion, with the majority of related AEs being Grade 1 or 2. The most common related AEs were nausea and lymphopenia (observed in three out of nine participants [33.3%], for each AE). The only AE that was Grade 3 or above was lymphopenia observed in three participants, some of whom had bone metastasis at baseline and/or had received multiple lines of therapy, including taxane and an investigational agent, prior to enrolment in the SECuRE study. There have been no overall renal toxicity or electrocardiogram (ECG) changes observed in these participants. In the combination enzalutamide arm, no new AEs (or worsening of AEs) related to ⁶⁷Cu-SAR-bisPSMA have been observed to date.

Trial participant with no detectable disease after 3 cycles of ⁶⁷Cu-SAR-bisPSMA

One of the participants in the Cohort Expansion was a 64-year-old man with bone metastases and baseline PSA of 5.4 ng/mL prior to entering the SECuRE study. Following his first cycle of ⁶⁷Cu-SAR-bisPSMA, this participant showed a dramatic 95.2% reduction in PSA. He went on to receive 2 more cycles of ⁶⁷Cu-SAR-bisPSMA and achieved undetectable PSA levels. In a follow-up bone scan and CT no metastatic disease was observed. This participant only exhibited mild (Grade 1) related AEs, most of which were gastrointestinal events, with no haematological or renal AEs observed. The participant reported having excellent quality of life following the treatment.

The interim data from this Phase II continues to confirm the favourable safety profile and promising efficacy seen in previous cohorts of the SECuRE trial^[1] and supports the continuation of the trial with the aim to progress to a registrational Phase III study.

Clarity's Executive Chairperson, Dr Alan Taylor, commented, "SAR-bisPSMA continues generating world-class data in both theranostic and diagnostic trials. The combination of the optimised dimer 'bis' structure with the benefits of copper isotopes, enabled by the proprietary sarcophagine technology, is proving to have created a product that is here to challenge the current treatment and diagnostic paradigms in radiopharmaceuticals.

"We have already seen a glimpse of the effects of ⁶⁷Cu-SAR-bisPSMA through our Dose Escalation cohorts with additional and similar data being generated in the Cohort Expansion phase, demonstrating once again excellent efficacy and safety results of ⁶⁷Cu-SAR-bisPSMA.

"All of the participants with evaluable data treated in the Phase II to date have shown declines in PSA, with the majority showing PSA decreases of more than 50% and mostly having only mild or moderate AEs. Most of these patients have been treated with more than 5 systemic treatment regiments and had bone metastasis prior to entering the SECuRE study. Although the number of participants with evaluable data to date is small, it is incredible to see yet another extraordinary case where a patient who had bone metastasis prior to entering the study achieved undetectable PSA following ⁶⁷Cu-SAR-bisPSMA treatment, with no disease observed by anatomical and molecular imaging at the last assessments. This participant only experienced mild, transient AEs, most being gastrointestinal, and has reported having excellent quality of life following the treatment.

"Importantly, the work we have undertaken during the Dose Escalation Phase is now continuing to provide a strong foundation for us as we look ahead at protocol development and dosing for our Phase III clinical trial and commercialisation. As the participant numbers continue to increase with the trial enrollment, we continue to see very promising responses over and over again, giving us more confidence about the future of this product and its potential for commercialisation in metastatic castration-resistant prostate cancer (mCRPC). With three Fast Track Designations for the SAR-bisPSMA product and positive interactions with the US Food and Drug Administration (FDA) to date, we are working towards bringing this agent to clinicians and their patients around the world through the entirety of the prostate cancer journey, from first diagnosis to late-stage disease. All of these indications, being imaging in pre-definitive therapy and biochemical recurrence, as well as therapy in mCRPC, are blockbuster markets individually for prostate-specific membrane antigen (PSMA) targeted products, with an estimated combined market value of approximately US$10-15 billion by 2030. We are committed to continuing the development of this product, aiming to bring improved diagnostic and treatment options for prostate cancer in various stages of their disease."

About the SECuRE trial

The SECuRE trial (NCT04868604)^[2] is a Phase I/IIa theranostic trial for identification and treatment of participants with PSMA-expressing mCRPC using ⁶⁴Cu/⁶⁷Cu-SAR-bisPSMA. ⁶⁴Cu-SAR-bisPSMA is used to visualise PSMA-expressing lesions and select candidates for subsequent ⁶⁷Cu-SAR-bisPSMA therapy. The trial is a multi-centre, single arm, dose escalation study with a cohort expansion involving approximately 54 participants in the US. The overall aim of the trial is to determine the safety and efficacy of ⁶⁷Cu-SAR-bisPSMA for the treatment of prostate cancer.

The SECuRE trial consists of the Dose Escalation (Phase I) and Cohort Expansion (Phase II) Phases. Based on the data from the Dose Escalation Phase, which demonstrated a favourable safety profile and efficacy of ⁶⁷Cu-SAR-bisPSMA, the SECuRE trial progressed to the Cohort Expansion (Phase II) at an 8 GBq dose level as per the SRC recommendation (up to 6 cycles per patient in total)^[3].

Cohort 2 of the Dose Escalation phase of the trial, where participants were dosed with 8 GBq of ⁶⁷Cu-SAR-bisPSMA, demonstrated a very low rate of related AEs while all three participants achieved PSA declines of 80% or more (PSA80)^[1]. The Dose Escalation Phase also showed high PSA response rates of the mCRPC in the pre-chemotherapy setting with a favourable safety profile: 92% of pre-chemotherapy participants (12/13) demonstrated PSA drops greater than 35%, PSA reductions greater than 50% were reached in 61.5% (8/13) of participants, and reductions of 80% or more were achieved in 46.2% (6/13) of participants^[1]. These results supported the progress of the trial to its Cohort Expansion Phase using 8 GBq multi-dose in participants who had not received chemotherapy in the mCRPC setting.

Recruitment is currently ongoing into the Cohort Expansion Phase which will include 24 participants. A subset of participants will be treated with the combination of 8 GBq of ⁶⁷Cu-SAR-bisPSMA with enzalutamide (androgen receptor pathway inhibitor [ARPI]), in line with the positive results from the Enza-p trial^[4] and previous discussions with and advice from key global medical experts in the field of prostate cancer, including the Company's Clinical Advisory Board members, Prof Louise Emmett and Prof Oliver Sartor, as well as the SRC.

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word "bis", which reflects a novel approach of connecting two PSMA-targeting agents to Clarity's proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or ⁶⁴Cu) for imaging and copper-67 (Cu-67 or ⁶⁷Cu) for therapy.

⁶⁷Cu-SAR-bisPSMA and ⁶⁴Cu-SAR-bisPSMA are unregistered products. The safety and efficacy of ⁶⁷Cu-SAR-bisPSMA and ⁶⁴Cu-SAR-bisPSMA have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide^[5]. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the US and around 35,770 deaths from the disease^[6].

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing TCTs based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

For more information, please contact: